BioLife Solutions, Inc.
- Jurisdiction
United States - LEI
549300G2IVCMC2TJDW72 - ISIN
US09062W2044 (BLFS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. Read full profile
Fundamentals
- Net revenue
€65.26M - Gross margin
82.7% - EBIT
-€14.70M - EBIT margin
-22.5% - Net income
-€4.72M - Net margin
-7.2%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Aebersold Sarah | Chief Human Resources Officer |
|
|
|
|
| Berard Todd | Chief Marketing Officer |
|
|
|
|
| Foster Karen A. | Chief Quality and Operations |
|
|
|
|
| Mathew Aby J. | EVP & Chief Scientific Officer |
|
|
|
|
| Werner Sean | Chief Technology Officer |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)